Dyne Therapeutics' (DYN) "Buy" Rating Reiterated at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright's price target indicates a potential upside of 246.57% from the company's previous close.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Robert W. Baird assumed coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an "outperform" rating and a $46.00 target price on the stock. StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. Baird R W upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $49.91.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded down $7.18 during trading hours on Friday, hitting $15.87. The stock had a trading volume of 9,825,974 shares, compared to its average volume of 2,482,390. The stock's fifty day simple moving average is $27.29 and its 200 day simple moving average is $34.15. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -4.46 and a beta of 1.16. Dyne Therapeutics has a 1-year low of $14.79 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, research analysts anticipate that Dyne Therapeutics will post -3.45 EPS for the current year.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dirk Kersten sold 23,671 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. The trade was a 19.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 44,742 shares of company stock valued at $1,443,246. Company insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

Large investors have recently made changes to their positions in the business. FMR LLC raised its position in shares of Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after acquiring an additional 3,707,734 shares during the period. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock worth $244,755,000 after purchasing an additional 2,189,339 shares in the last quarter. State Street Corp grew its holdings in shares of Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company's stock valued at $130,816,000 after buying an additional 440,890 shares during the period. RTW Investments LP increased its position in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock valued at $244,926,000 after buying an additional 431,503 shares in the last quarter. Finally, RA Capital Management L.P. raised its stake in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock worth $229,211,000 after buying an additional 331,940 shares during the period. Institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.